Painless eye drops could save sight in kids with brain tumors
NCT ID NCT05733572
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new painless nerve growth factor eye drop (CHF6467) in 36 children and young adults with optic pathway glioma, a brain tumor that often causes vision loss. The goal is to see if the drops can protect or improve vision without the pain side effects of standard nerve growth factor. Participants receive either the active eye drops or a placebo, and their vision is monitored over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPTIC PATHWAY GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Catholic University, Policlinico A. Gemelli (Hospital)
Rome, 00168, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a parasite drug fight childhood brain tumors?
- New proton therapy aims to shield memory in kids with brain cancer
- New hope for kids with NF1 brain tumors: targeted drug may beat chemo
- New hope for kids with resistant tumors? early trial tests CUDC-907
- Experimental drug TURALIO takes on tough childhood cancers in early trial